IN
INAB.US In8bio Inc
- Market cap
- USD 8.86M
- P/E
- -
- P/B
- 0.63x
- ROE
- -136.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INAB.US undervalued?
Graham numberThe Graham number of In8bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
In8bio Inc fundamental analysis
No fundamental analysis for In8bio Inc yet.
In8bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; a…
Full company profileIn8bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
In8bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -96.0K | -96.0K | -96.0K | -251K | -1.10M | -2.50M | -2.66M | -2.50M | - |
| Operating Income | -2.00M | -5.13M | -8.56M | -14.7M | -28.5M | -30.3M | -30.4M | -19.9M | -19.5M |
| EBITDA | -1.97M | -5.04M | -8.47M | -13.9M | -27.4M | -27.5M | -26.9M | -16.9M | -17.4M |
| Net Income | -2.08M | -5.13M | -8.56M | -14.7M | -27.4M | -30.0M | -30.4M | -19.4M | -19.3M |
| EPS | -3.23 | -7.96 | -13 | -23 | -39 | -30 | -17 | -4.44 | -0.99 |
| Balance Sheet | |||||||||
| Total Assets | 5.90M | 1.13M | 20.9M | 42.2M | 33.0M | 33.7M | 20.9M | 32.3M | 18.7M |
| Total Liabilities | 1.25M | 1.48M | 2.59M | 4.04M | 10.3M | 8.77M | 6.47M | 4.72M | 6.41M |
| Shareholders' Equity | 4.65M | -346K | 18.3M | 38.2M | 22.7M | 24.9M | 14.5M | 27.6M | 14.2M |
| Cash & Short-term Investments | 4.99M | 610K | 18.0M | 37.0M | 18.2M | 21.3M | 11.1M | 27.1M | 14.0M |
| Total Debt | - | - | 174K | 2.41M | 5.87M | 4.89M | 5.03M | 2.78M | 2.75M |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.77M | -4.80M | -7.13M | -13.5M | -24.1M | -23.3M | -24.1M | -12.7M | -16.8M |
| Capital Expenditure | 757K | 330K | 309K | 309K | 3.71M | 600K | 104K | 0.00 | 324K |
| Free Cash Flow | -3.53M | -5.13M | -7.13M | -13.8M | -27.8M | -23.9M | -24.3M | -12.7M | -17.1M |
| Ratios | |||||||||
| ROE | -44.8% | - | -46.7% | -38.4% | -120.6% | -120.3% | -210.2% | -70.5% | -136.1% |
| ROA | -35.3% | -454.3% | -40.9% | -34.7% | -83.0% | -89.0% | -145.3% | -60.2% | -103.2% |
| Debt to Equity | - | - | 0.01x | 0.06x | 0.26x | 0.20x | 0.35x | 0.10x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
In8bio Inc dividends
In8bio Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:30 on Jun 6, 2025.
Who owns In8bio Inc
- Insiders 6.91%
- Institutions 35.33%
- Public & others 57.76%
- Shares outstanding 10.8M
- Free float 7.87M
Top funds holding INAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 582K | 5.91% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 332K | 3.37% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 46.1K | 0.47% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 12.2K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.04K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding INAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 944K | 9.58% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 915K | 9.28% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 695K | 7.05% | +4.80% | Jun 2026 |
| Vanguard Capital Management, LLC | 88.9K | 0.90% | 0.00% | Jun 2026 |
| BIOS CAPITAL MANAGEMENT, LP | 81.0K | 0.82% | -51.76% | Jun 2026 |
| Geode Capital Management, LLC | 72.6K | 0.74% | -15.87% | Jun 2026 |
| Citadel Advisors Llc | 63.1K | 0.64% | 0.00% | Jun 2026 |
| Oppenheimer & Co Inc | 63.0K | 0.64% | +162.31% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 43.6K | 0.44% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 33.9K | 0.34% | +180.31% | Sep 2026 |
| CapTrust Financial Advisors | 33.3K | 0.34% | 0.00% | Jun 2026 |
| Texas Capital Bank Wealth Management Services Inc | 24.4K | 0.25% | +2.76% | Jun 2026 |
| Northern Trust Corp | 21.7K | 0.22% | +6.33% | Jun 2026 |
| Tower Research Capital LLC | 3.74K | 0.04% | +195.49% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 2.79K | 0.03% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 768.00 | 0.01% | 0.00% | Jun 2026 |
| BlackRock Inc | 84.00 | 0.00% | 0.00% | Jun 2026 |
| Rockefeller Capital Management L.P. | 83.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 28.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 1.00 | 0.00% | -99.79% | Jun 2026 |
In8bio Inc company profile
- Company name
- In8bio Inc
- Ticker
- INAB.US
- Exchange
- USA Stocks
- Listed since
- Jul 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- 350 5th Avenue, New York, NY, United States, 10118
- Phone
- 646 600 6438
- Website
- in8bio.com
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
In8bio Inc management
5- Mr. Tai-Wei HoCo-Founder, CEO & Director · born 1977
- Dr. Kate Rochlin Ph.D.President & COO · born 1982
- Mr. Patrick McCall CPACFO & Secretary · born 1984
- Dr. Lawrence S. Lamb Ph.D.Executive VP, Co-Founder & Chief Scientific Officer · born 1955
- Dr. Oxana Polyakova Ph.D.Senior Vice President of Research & Development